Product news

Share this article:
Sanofi-Aventis and Bristol-Myers Squibb said the FDA Administration has approved a supplemental new drug application for a 300 mg tablet of the antiplatelet drug Plavix (clopidogrel bisulfate). The Plavix 300 mg tablet will facilitate the use of the FDA approved loading dose for appropriate acute coronary syndrome patients as soon as possible after hospital admission.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions